On Friday, Amgen filed a complaint for patent infringement under the BPCIA against yet another developer of a biosimilar of Neulasta® (pegfilgrastim). Amgen has sued Mylan in the Western District of Pennsylvania for infringement of U.S. Patent Nos. 8,273,707 and 9,643,997, which Amgen alleges “claim methods of purifying proteins used…